| Literature DB >> 29662964 |
Shekoufeh Atashpour1,2, Hossein Kargar Jahromi1,3, Zahra Kargar Jahromi3, Mozhgan Maleknasab4.
Abstract
BACKGROUND: Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in women which affect fertility. Clomiphene citrate is used as first-line treatment for this disorder, which is associated with some complications and therapeutic resistance.Entities:
Keywords: Clomiphene citrate; Ginger; Polycystic ovarian syndrome
Year: 2017 PMID: 29662964 PMCID: PMC5894472
Source DB: PubMed Journal: Int J Reprod Biomed ISSN: 2476-3772
Figure 1Effect of estradiol valerate, clomiphene and ginger extract on serum levels of LH. All data represent Mean±SEM. a: Significant difference (p<0.001) between PCO groups and sham/control groups, b: Significant difference (p<0.001) between treatment groups and sham/control groups, c: Significant difference (p<0.001) between PCO groups and treatment groups
Figure 3Effect of estradiol valerate, clomiphene and ginger extract on serum levels of estrogen. All data represent Mean±SEM. a: Significant difference (p<0.001) between PCO groups and sham/control groups, b: Significant difference (p<0.001) between treatment groups and sham/control groups, c: Significant difference (p<0.001) between PCO groups and treatment groups
Figure 4Effect of estradiol valerate, clomiphene and ginger extract on serum levels of progesterone. All data represent Mean±SEM. a: Significant difference (p<0.001) between PCO groups and sham/control groups, b: Significant difference (p<0.001) between treatment groups and sham/control groups, c: Significant difference (p<0.001) between PCO groups and treatment groups
Serum LH, FSH, estrogen, progesterone levels in the studied rats
|
|
| |||
|---|---|---|---|---|
|
|
|
|
| |
| Control (60 day) | 8.22 ± 0.42 | 11.94 ± 0.41 | 264.04 ± 5.59 | 372.16 ± 4.47 |
| Control (89 day) | 8.28 ± 0.24 | 12.66 ± 0.39 | 259.88 ± 5.43 | 369.3 ± 7.91 |
| Sham (60 day) | 8.14 ± 0.34 | 11.38 ± 0.56 | 250.54 ± 5.82 | 366.76 ± 5.62 |
| Sham (89 day) | 8.36 ± 0.32 | 11.6 ± 0.51 | 262.64 ± 5.69 | 365.8 ± 5.56 |
| Experimental group 1 | 12 ± 0.46 | 6.34 ± 1.15 | 372.64 ± 5.12 | 251.54 ± 6.77 |
| Experimental group 2 | 11.94 ± 0.53 | 4.78 ± 0.23 | 375.34 ± 5.33 | 249.94 ± 2.99 |
| Experimental group 3 | 9.06 ± 0.36 | 9.96 ± 0.28 | 281.58 ± 5.11 | 320.3 ± 4.16 |
| Experimental group 4 | 9.8 ± 0.28 | 6.7 ± 0.43 | 322.48 ± 3.43 | 291.94 ± 7.94 |
| Experimental group 5 | 9.22 ± 0.33 | 9.08 ± 0.66 | 299.58 ± 8.65 | 323.08 ± 3.79 |
| P-value | <0.001 | <0.001 | <0.001 | <0.001 |
All data are presented as the Mean ± SEM.
Statistical analysis was carried out using One-way analysis of variance (ANOVA) followed by Duncan post hoc test.
Statistical p<0.05 was considered significant
LH= Luteinizing hormone
FSH= Follicle stimulating hormone
: Significant difference (p<0.001) between PCO groups and sham/control groups,
: Significant difference (p<0.001) between treatment groups and sham/control groups,
: Significant difference (p<0.001) between PCO groups and treatment groups.